This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PRELIMINARY REPORT

WILLIAM E. LONG, M.D.

Arch Derm Syphilol. 1943;47(2):226-234.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The therapeutic efficiency of any arsenical preparation for the treatment of syphilis is judged largely from the response of early syphilis (primary and secondary) to its use. In order to evaluate a new drug the most important factors to consider are: (1) the rapid control of infectiousness, (2) the healing of lesions, (3) the rate and permanence of serologic response, (4) the prevention of infectious or serologic relapse and progression of the disease, (5) low incidence of involvement of the central nervous system in early syphilis, (6) a beneficial effect on late syphilis and (7) a low incidence of untoward or toxic reactions. A drug which would meet these requirements would indeed be ideal.

Arsphenamine is, even today, the most active of the arsenical preparations in common use, and yet, because of the difficulties encountered in its administration and its untoward effects, it has been largely replaced by drugs which . . . [Full Text PDF of this Article]

Author Affiliations
BOSTON

Squibb Fellow in Medicine.

From the Evans Memorial, Massachusetts Memorial Hospitals, and the Department of Medicine, Boston University School of Medicine.

Footnotes
This study was made possible by a grant from the E. R. Squibb and Sons Company, New Brunswick, N. J.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?